Literature DB >> 15764611

Long-term outcome in relation to renal sympathetic activity in patients with chronic heart failure.

Magnus Petersson1, Peter Friberg, Graeme Eisenhofer, Gavin Lambert, Bengt Rundqvist.   

Abstract

AIMS: Although cardiac sympathetic activation is associated with adverse outcome in patients with chronic heart failure (CHF), the influence of renal sympathetic activity on outcome is unknown. We assessed the hypothesis that renal noradrenaline (NA) spillover is a predictor of the combined endpoint of all-cause mortality and heart transplantation in CHF. METHODS AND
RESULTS: Sixty-one patients with CHF, New York Heart Association (NYHA) I-IV (66% NYHA III-IV), and left ventricular ejection fraction (LVEF) 26+/-9% (mean+/-SD) were studied with cardiac and renal catheterizations at baseline and followed for 5.5+/-3.7 years (median 5.5 years, range 12 days to 11.6 years). Nineteen deaths and 13 cases of heart transplantation were registered. Only renal NA spillover above median, 1.19 (interquartile range 0.77-1.43) nmol/min, was independently associated with an increased relative risk (RR) of the combined endpoint (RR 3.1, 95% CI 1.2-7.6, P=0.01) in a model also including total body NA spillover, LVEF, glomerular filtration rate (GFR), renal blood flow, cardiac index, aetiology, and age.
CONCLUSION: Renal noradrenergic activation has a strong negative predictive value on outcome independent of overall sympathetic activity, GFR, and LVEF. These findings suggest that treatment regimens that further reduce renal noradrenergic stimulation could be advantageous by improving survival in patients with CHF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15764611     DOI: 10.1093/eurheartj/ehi184

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  48 in total

Review 1.  Renal sympathetic nerve ablation: the new frontier in the treatment of hypertension.

Authors:  Markus P Schlaich; Henry Krum; Paul A Sobotka
Journal:  Curr Hypertens Rep       Date:  2010-02       Impact factor: 5.369

Review 2.  Renal denervation: effects on atrial electrophysiology and arrhythmias.

Authors:  Dominik Linz; Arne van Hunnik; Christian Ukena; Sebastian Ewen; Felix Mahfoud; Stephan H Schirmer; Matthias Lenski; Hans-Ruprecht Neuberger; Ulrich Schotten; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2014-03-29       Impact factor: 5.460

3.  Central angiotensin type 1 receptor blockade decreases cardiac but not renal sympathetic nerve activity in heart failure.

Authors:  Rohit Ramchandra; Sally G Hood; Anna M D Watson; Andrew M Allen; Clive N May
Journal:  Hypertension       Date:  2012-02-06       Impact factor: 10.190

Review 4.  Review of the state of renal nerve ablation for patients with severe and resistant hypertension.

Authors:  Vinay Gulati; William B White
Journal:  J Am Soc Hypertens       Date:  2013-08-15

5.  The hypothalamic paraventricular nucleus may not be at the heart of sympathetic outflow.

Authors:  Sean D Stocker; Kevin D Monahan; Lawrence I Sinoway
Journal:  J Physiol       Date:  2013-01-01       Impact factor: 5.182

Review 6.  Novel and nonpharmacologic approaches to cardio-protection in hypertension.

Authors:  Luca Donazzan; Felix Mahfoud; Dominik Linz; Sebastian Ewen; Christian Ukena; Michael Böhm
Journal:  Curr Hypertens Rep       Date:  2014-05       Impact factor: 5.369

Review 7.  Renal Denervation: Where to Now?

Authors:  Neil J Wimmer; Laura Mauri
Journal:  Curr Cardiol Rep       Date:  2015-12       Impact factor: 2.931

Review 8.  Angiotensin II, sympathetic nerve activity and chronic heart failure.

Authors:  Yutang Wang; Sai-Wang Seto; Jonathan Golledge
Journal:  Heart Fail Rev       Date:  2014-03       Impact factor: 4.214

Review 9.  Sympathetic Activation in Chronic Heart Failure: Potential Benefits of Interventional Therapies.

Authors:  Kamila Lachowska; Marcin Gruchała; Krzysztof Narkiewicz; Dagmara Hering
Journal:  Curr Hypertens Rep       Date:  2016-07       Impact factor: 5.369

Review 10.  Renal denervation: a novel non-pharmacological approach in heart failure.

Authors:  Michael Böhm; Sebastian Ewen; Dominik Linz; Jan-C Reil; Stephan Schirmer; Christian Ukena; Felix Mahfoud
Journal:  J Cardiovasc Transl Res       Date:  2014-02-28       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.